Neoadjuvant modified TPF (docetaxel, cisplatin, fluorouracil) for patients unfit to standard TPF in locally advanced head and neck squamous cell carcinoma: a study of 48 patients

TPF (docetaxel, cisplatin, fluorouracil) is the standard chemotherapy used for induction in locally advanced head and neck squamous cell carcinoma (LAHNSCC). Its toxicity limits it to younger patients with good functional status and without significant comorbidity. Since modified TPF (mTPF) demonstr...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Fayette, Jérôme, Fontaine-Delaruelle, Clara, Ambrun, Alexis, Daveau, Clémentine, Poupart, Marc, Ramade, Antoine, Zrounba, Philippe, Neidhardt, Eve-Marie, Péron, Julien, Diallo, Alpha, Céruse, Philippe
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2016
Matèries:
Clinical Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5095077/
https://ncbi.nlm.nih.gov/pubmed/27119503
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.8934
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars